Literature DB >> 25529753

Advancements in the development of subunit influenza vaccines.

Naru Zhang1, Bo-Jian Zheng2, Lu Lu3, Yusen Zhou4, Shibo Jiang5, Lanying Du6.   

Abstract

The ongoing threat of influenza epidemics and pandemics has emphasized the importance of developing safe and effective vaccines against infections from divergent influenza viruses. In this review, we first introduce the structure and life cycle of influenza A viruses, describing major influenza A virus-caused pandemics. We then compare different types of influenza vaccines and discuss current advancements in the development of subunit influenza vaccines, particularly those based on nucleoprotein (NP), extracellular domain of matrix protein 2 (M2e) and hemagglutinin (HA) proteins. We also illustrate potential strategies for improving the efficacy of subunit influenza vaccines.
Copyright © 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hemagglutinin; Influenza A virus; Matrix protein; Nucleoprotein; Subunit vaccines

Mesh：

Substances：

Year:  2014        PMID： 25529753      PMCID： PMC4336774          DOI： 10.1016/j.micinf.2014.12.006

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  119 in total

1.  Activation of influenza virus RNA polymerase by the 5' and 3' terminal duplex of genomic RNA.

Authors:  M-T Michael Lee; Klaus Klumpp; Paul Digard; Laurence Tiley
Journal:  Nucleic Acids Res       Date:  2003-03-15       Impact factor: 16.971

2.  Immunogenicity and efficacy of a recombinant adenovirus expressing hemagglutinin from the H5N1 subtype of swine influenza virus in mice.

Authors:  Yunpu Wu; Chuanling Qiao; Huanliang Yang; Yan Chen; Xiaoguang Xin; Hualan Chen
Journal:  Can J Vet Res       Date:  2014-04       Impact factor: 1.310

Review 3.  Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.

Authors:  Alina Isai; Julie Durand; Steven Le Meur; Ana Hidalgo-Simon; Xavier Kurz
Journal:  Vaccine       Date:  2012-09-26       Impact factor: 3.641

4.  A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge.

Authors:  Guangliang Liu; Fangfang Zhang; Jianzhong Shi; Guobing Tian; Hualan Chen; Kangzheng Yu; Qingwen Meng
Journal:  Vaccine       Date:  2013-09-19       Impact factor: 3.641

5.  Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.

Authors:  Y Shen; S I Muramatsu; K Ikeguchi; K I Fujimoto; D S Fan; M Ogawa; H Mizukami; M Urabe; A Kume; I Nagatsu; F Urano; T Suzuki; H Ichinose; T Nagatsu; J Monahan; I Nakano; K Ozawa
Journal:  Hum Gene Ther       Date:  2000-07-20       Impact factor: 5.695

6.  Genetic reassortment of avian, swine, and human influenza A viruses in American pigs.

Authors:  N N Zhou; D A Senne; J S Landgraf; S L Swenson; G Erickson; K Rossow; L Liu; K j Yoon; S Krauss; R G Webster
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 7.  Attenuated influenza virus vaccines with modified NS1 proteins.

Authors:  Jüergen A Richt; Adolfo García-Sastre
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

8.  Prospects for control of emerging infectious diseases with plasmid DNA vaccines.

Authors:  Ronald B Moss
Journal:  J Immune Based Ther Vaccines       Date:  2009-09-07

9.  Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.

Authors:  Jian Luo; Dan Zheng; Wenjie Zhang; Fang Fang; Hanzhong Wang; Ying Sun; Yahong Ding; Chengfei Xu; Quanjiao Chen; Hongbo Zhang; Ding Huang; Bing Sun; Ze Chen
Journal:  Virol J       Date:  2012-11-23       Impact factor: 4.099

10.  Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults.

Authors:  Jessica A Chichester; R Mark Jones; Brian J Green; Mark Stow; Fudu Miao; George Moonsammy; Stephen J Streatfield; Vidadi Yusibov
Journal:  Viruses       Date:  2012-11-19       Impact factor: 5.048
View more
  17 in total

1.  Replication and Transmission of the Novel Bovine Influenza D Virus in a Guinea Pig Model.

Authors:  Chithra Sreenivasan; Milton Thomas; Zizhang Sheng; Ben M Hause; Emily A Collin; David E B Knudsen; Angela Pillatzki; Eric Nelson; Dan Wang; Radhey S Kaushik; Feng Li
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

2.  Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.

Authors:  Jian Tang; Naru Zhang; Xinrong Tao; Guangyu Zhao; Yan Guo; Chien-Te K Tseng; Shibo Jiang; Lanying Du; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Towards the knowledge-based design of universal influenza epitope ensemble vaccines.

Authors:  Qamar M Sheikh; Derek Gatherer; Pedro A Reche; Darren R Flower
Journal:  Bioinformatics       Date:  2016-07-10       Impact factor: 6.937

Review 4.  Iminosugars: Promising therapeutics for influenza infection.

Authors:  Beatrice Ellen Tyrrell; Andrew Cameron Sayce; Kelly Lyn Warfield; Joanna Louise Miller; Nicole Zitzmann
Journal:  Crit Rev Microbiol       Date:  2016-12-08       Impact factor: 7.624

5.  The Matrix protein M1 from influenza C virus induces tubular membrane invaginations in an in vitro cell membrane model.

Authors:  David Saletti; Jens Radzimanowski; Gregory Effantin; Daniel Midtvedt; Stéphanie Mangenot; Winfried Weissenhorn; Patricia Bassereau; Marta Bally
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

Review 6.  Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.

Authors:  Chao Jiang; Xingang Yao; Yulin Zhao; Jianmin Wu; Pan Huang; Chunhua Pan; Shuwen Liu; Chungen Pan
Journal:  Microbes Infect       Date:  2020-05-13       Impact factor: 2.700

Review 7.  An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.

Authors:  Hamid Motamedi; Marzie Mahdizade Ari; Shirin Dashtbin; Matin Fathollahi; Hadi Hossainpour; Amirhoushang Alvandi; Jale Moradi; Ramin Abiri
Journal:  Int Immunopharmacol       Date:  2021-05-06       Impact factor: 5.714

8.  An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin.

Authors:  Li Song; Dan Xiong; Xilong Kang; Yun Yang; Jing Wang; Yaxin Guo; Hui Xu; Sujuan Chen; Daxin Peng; Zhiming Pan; Xinan Jiao
Journal:  BMC Biotechnol       Date:  2015-08-19       Impact factor: 2.563

9.  Oral immunization of a non-recombinant Lactococcus lactis surface displaying influenza hemagglutinin 1 (HA1) induces mucosal immunity in mice.

Authors:  Pui-Fong Jee; Vunjia Tiong; Meng-Hooi Shu; Jing-Jing Khoo; Won Fen Wong; Raha Abdul Rahim; Sazaly AbuBakar; Li-Yen Chang
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

Review 10.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.